Haoxi Health Technology Ltd (NASDAQ:HAO) ("Haoxi" or the "Company"), today announced that it has entered into a definitive agreement with certain investors for the purchase and sale of an aggregate of 10,000,000 of the Company’s Class A Ordinary Shares, par value $0.32 per share (the "Shares") (or pre-funded warrants in lieu thereof) at a purchase price of $0.40 per share in a registered direct offering. The purchase price for the pre-funded warrants is identical to the purchase price for Shares, less the exercise price of $0.33 per share.

The aggregate gross proceeds to the Company of this offering are expected to be approximately $4 million. The transaction is expected to close on or about July 13, 2026, subject to the satisfaction of customary closing conditions.

Univest Securities, LLC is acting as the sole placement agent.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.